NCT05005182View on ClinicalTrials.gov

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

April 17, 2023

Study Completion Date

June 17, 2023

Conditions
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise SpecifiedMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspirate

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspirate

DRUG

Hydroxyurea

Given PO

BIOLOGICAL

Luspatercept

Given SC

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85054

Mayo Clinic Hospital in Arizona, Phoenix

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05005182 - Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts | Biotech Hunter | Biotech Hunter